Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cigna Corp (NY: CI )

328.90 +5.51 (+1.70%)
Streaming Delayed Price Updated: 2:30 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cigna Corp

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
PBMs Express Scripts, Caremark, and Optum challenge the FTC's administrative proceedings, arguing it violates constitutional rights and threatens the stability of drug pricing. 
Via Benzinga
Price Over Earnings Overview: Cigna
Via Benzinga
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul
Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga's Deal Dispatch has the latest M&A updates. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Cigna Stock Popped Today
The healthcare company put merger rumors to bed. 
Via The Motley Fool
3 Healthcare Stocks For Long-Term Growth And Dividends
Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time. 
Via Talk Markets
Cigna’s Stock Surges After Dropping Humana Merger Plans
Cigna Group has decided not to merge with Humana, leading to a rise in Cigna's stock and a drop in Humana's stock. 
Via Talk Markets
MARA Holdings, RadNet, Bit Digital, Coinbase And Other Big Stocks Moving Higher On Monday
Via Benzinga
Cigna Not Pursuing Humana Merger, Stock Soars
Cigna Group reaffirms 2024 EPS outlook, reports strong Q3 results, and clarifies it is not pursuing a merger with Humana amid ongoing speculation. 
Via Benzinga
Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization. 
Via Benzinga
Topics Government
Exposures Political
Price Over Earnings Overview: Cigna
Via Benzinga
NYSE:CI is an undervalued gem with solid fundamentals.
THE CIGNA GROUP (NYSE:CI): good value for what you're paying. 
Via Chartmill
Investors seeking growth at a reasonable cost should explore NYSE:CI.
THE CIGNA GROUP (NYSE:CI) is showing good growth, while it is not too expensive. 
Via Chartmill
MarketBeat Week in Review – 10/28 - 11/1
Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
Via Benzinga
11 Analysts Assess Cigna: What You Need To Know
Via Benzinga
Here's How Much You Would Have Made Owning Cigna Stock In The Last 15 Years
Via Benzinga
Cigna Group (CI) Q3 2024 Earnings Call Transcript
CI earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Cigna's Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management's Specialty Drugs, New Clients
Cigna reports Q3 sales of $63.7 billion, a 30% YoY increase, driven by Evernorth growth. Adjusted EPS of $7.51 beats estimates. 2024 EPS guidance reaffirmed. 
Via Benzinga
The Cigna Group Reports $63.7 Billion In Q3 Total Revenues, Better Than Expected
The Cigna Group has reported impressive financial results for the third quarter of 2024. 
Via Talk Markets
Cigna Considers Humana Acquisition – What It Means for the Stocks
Rumors swirl around a potential Cigna (CI) and Humana (HUM) merger, but Medicare Advantage costs pose a significant challenge, making the merger risky. 
Via MarketBeat
Jim Cramer: Buy Broadcom, But Stay Away From These Stocks
The "Mad Money" host recommends buying Broadcom, but staying away from this bus manufacturer. "I just don't see the growth." 
Via Benzinga
Why Cigna Group Stock Got Mashed on Monday
A media report stated that the company is determined to grow with a major merger deal. 
Via The Motley Fool
Stocks Fall As Treasury Yields, Dollar Rise; Nvidia Hits Record Highs: What's Driving Markets Monday?
U.S. major indices fell on Monday as rising Treasury yields and a strengthening dollar dampened risk sentiment. Investors are reassessing the economic outlook and weighing potential risks tied to the... 
Via Benzinga
Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms
Cigna and Humana are in early-stage merger discussions after a year-long pause. Amid financial pressure, Humana's Medicare Advantage star ratings have plummeted, impacting future revenue. 
Via Benzinga
Cigna-Humana Merger Talks Back On With Tables Turned; 2024 Election Is Key
Cigna-Humana merger talks are back on, nearly one year after the first try. The price may be more affordable after CI stock outperformed, while HUM struggled. 
Via Investor's Business Daily
Market Briefing For Monday, Oct 21
Investors need to recognize that this time of year not only are more 'shakeouts' than we've seen likely; but tax-selling and shuffling (rearranging the Titanic deckchairs to some degree) is to be... 
Via Talk Markets
SAP, Nucor And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Pharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO
CVS Health replaces CEO Karen Lynch with David Joyner as the company struggles with lower earnings projections and rising medical costs. Q3 2024 results, including a $1.1 billion charge, are expected... 
Via Benzinga
CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit
The FTC has filed a formal complaint accusing CVS, Cigna, and UnitedHealth of engaging in anti-competitive practices that inflate insulin prices. The complaint claims the PBMs' focus on rebates raises... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.